Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.7% in the 1st quarter, HoldingsChannel reports. The fund owned 32,433 shares of the life sciences company’s stock after acquiring an additional 841 shares during the period. IFM Investors Pty Ltd’s holdings in Illumina were worth $4,454,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. First Trust Direct Indexing L.P. acquired a new position in shares of Illumina during the 1st quarter worth about $229,000. Norden Group LLC purchased a new stake in Illumina during the first quarter worth approximately $584,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Illumina by 0.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 386,241 shares of the life sciences company’s stock valued at $53,039,000 after purchasing an additional 2,240 shares in the last quarter. Trivant Custom Portfolio Group LLC increased its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the last quarter. Finally, 180 Wealth Advisors LLC raised its holdings in Illumina by 8.6% during the first quarter. 180 Wealth Advisors LLC now owns 15,474 shares of the life sciences company’s stock worth $2,125,000 after purchasing an additional 1,231 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ILMN. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a report on Thursday, January 4th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $167.70.

Illumina Price Performance

Illumina stock traded up $1.23 during trading hours on Friday, hitting $122.28. The stock had a trading volume of 829,331 shares, compared to its average volume of 1,470,247. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91. The stock has a market capitalization of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19. The stock’s fifty day moving average is $131.51 and its two-hundred day moving average is $127.39. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. The firm’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.14 EPS. As a group, analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.